Market news — every asset we track

Assets

KPRX

Kiora Pharmaceuticals names Keith Lane clinical development head

Sep 8Investing.com

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunitiesEncinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience

Sep 8Yahoo Finance

KPRX

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and...

Aug 19Yahoo Finance

KPRX

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 7Yahoo Finance

KPRX

This is the newest page. Registered accounts read further back.